The shrinking return on investment for Nordic innovation - Pharmaceutical Technology

Nordic biopharma innovation outpaces commercialization as regional biotechs struggle to raise the capital needed to upscale. Nordic biopharma innovation outpaces commercialisation as regional biotechs struggle to raise the capital needed to upscale. Biotechs based in Nordic countries say difficulties raising capital are holding the region back from making the most of its innovative excellence in biopharma. Photo by crispypictures/iStock via Getty Images. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news…

Source: Pharmaceutical Technology